About SynDevRx
Management Team

The SynDevRx executive team has established an efficient system for quickly and productively advancing drugs through the early stages of clinical proof of concept.

Key Management and Consultants

Bradley J Carver, co-Founder, President and CEO

Brad has a 16 year history in Biotech, in which he has consistently created value for his investors. As President and CEO, he increased the value of his publicly traded company GlycoGenesys (Russell 2000 and NASDAQ listed) from $25M to well over $500M in less than 5 years.  He successfully completed a partnership deal with Elan Pharmaceuticals, and developed and put into clinical trials one of the world's first complex carbohydrate cancer drug candidates GCS100, which continues in clinical trials as a promising drug candidate.

Brad’s thoughtful execution, resourcefulness and team building skills allowed the company to solve unique and complex manufacturing and characterization issues, identify and characterize multiple mechanisms of action for GCS-100 that, previous to his work, were not thought possible for a naturally derived complex carbohydrate.   He led the clinical trial program design effort and was key in selecting the target indications.

Brad attended Michigan State University, where he received his BA in Business.

James M. Shanahan, co-Founder, VP Business Development

Jim is a serial entrepreneur with over 12 years of successful experience in Business Development.  Previously, he was co-founder and VP Marketing at JAM Technologies, Inc., where he successfully completed licensing deals of the company's novel platform technology to AKM Japan, and was instrumental in forming strategic co-development partnerships with Intel and others.  Jim also built the company's sales and distribution channels throughout Asia, plus established the company's market positioning with industry leaders including Bose, Apple Computer, Dell, National Semiconductor, and SRS among others.  He also was responsible for establishing all initial sales opportunities with major OEMs in Japan, Taiwan, China and Korea.

Jim managed all aspects of the company's operations from inception to the Series B round, including financing, legal, licensing, IP, and strategic planning. Jim has one issued patent from his work at JAM. Jim attended the University of Massachusetts at Amherst with concentrations in engineering, math and language, and L'Universite Catholique, Angers France.

 

John Petersen, Ph.D., VP Chemistry and Manufacturing

John is a synthetic chemist with over 20 years biotech experience. While a senior manager at GelTex, John was responsible for taking the polymeric drug Renagel® from concept through NDA in both US and European markets. John has the rare experience of taking a drug from pre-IND to approval.  He has unmatched expertise in polymeric drug development and manufacturing, which is critical to the success of SynDevRx, Inc. John completed his undergraduate degree at MIT, and his Ph.D. in chemistry at UC Berkeley under Dr. Rappaport.

 

Watch here for upcoming announcements on additional key management.